Amphastar Pharmaceuticals (AMPH) Research & Development (2013 - 2026)

Amphastar Pharmaceuticals has reported Research & Development for 14 years, with the latest figure at $22.2 million in Q2 2026.

• On a quarterly basis, Research & Development rose 10.38% year-over-year to $22.2 million in Q2 2026; TTM through Jun 2026 was $94.6 million, a 19.11% increase from a year earlier, with the FY2025 full-year figure at $85.8 million, up 16.14% from the prior year.
• Research & Development was $22.2 million for Q2 2026 at Amphastar Pharmaceuticals, down from $26.7 million in the prior quarter.
• The five-year high for Research & Development was $26.7 million in Q1 2026, with the low at $16.2 million in Q1 2022.
• Average Research & Development over 5 years is $19.8 million, with a median of $19.9 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Research & Development jumped 72.08% in 2022, then declined 26.12% in 2023.
• Over 5 years, Research & Development stood at $17.2 million in 2022, then advanced by 18.47% to $20.4 million in 2023, then declined by 11.15% to $18.1 million in 2024, then advanced by 28.51% to $23.3 million in 2025, then fell by 4.93% to $22.2 million in 2026.
• The last three Research & Development figures came in at $22.2 million (Q2 2026), $26.7 million (Q1 2026), and $23.3 million (Q4 2025), per Business Quant data.